If the two divisions were to split, it could mean as much as 30% upside for the stock, Credit Suisse analyst Edward Kelly wrote in a note.
But just how likely is a split between CVS and Caremark? Kelly noted that if Caremark's performance doesn't improve over the next year it could be highly likely.
"We find CVS's continued mismanagement of Caremark and its lack of insight into the underlying issues disturbing," he wrote. "That being said, we believe overwhelmingly negative investor sentiment has created a compelling risk/reward set-up in the stock. We continue to believe CVS's problems are fixable."While Caremark is experiencing some fundamental problems, Kelly still believes it's an attractive asset for a potential buyer. He also said that while a sale would be the best bet for CVS, a spin-off could also help the drugstore. In its fourth quarter, CVS reported lower profits and revenue and said it expects profit at its Caremark pharmacy benefits management to shrink further in 2011. This will mark the second consecutive year of profit declines at the division. Wall Street expected the company would begin to see improvements at Caremark, but CVS said a new multi-year contract with Aetna will drag on results. Other issues affecting Caremark include lower payments from pharmacy benefits programs for federal employees, less profitable contract renewals, and expenses related to cost cuts. CVS also said adjusted profit per prescription will continue to decline, moving closer to the levels reported by Caremark's competitors. The company does expect Caremark profit to start to grow in 2012. CVS acquired Caremark in 2007 for $27 billion. --Written by Jeanine Poggi in New York.
>To contact the writer of this article, click here: Jeanine Poggi. >To follow the writer on Twitter, go to http://twitter.com/jpoggi. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV